-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ivonescimab in Squamous Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ivonescimab in Squamous Non-Small Cell Lung Cancer report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ivonescimab in Squamous Non-Small Cell Lung Cancer Drug Details:...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Briquilimab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Briquilimab in Acute Myelocytic Leukemia (AML, Acute Myeloblastic Leukemia) report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Briquilimab in Acute Myelocytic Leukemia (AML, Acute...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Briquilimab in Myelodysplastic Syndrome
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Briquilimab in Myelodysplastic Syndrome report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Briquilimab in Myelodysplastic Syndrome Drug Details: Briquilimab (AMG-191) is under development for...
-
Product Insights
Likelihood of Approval and Phase Transition Success Rate Model – Briquilimab in Chronic Urticaria Or Hives
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Briquilimab in Chronic Urticaria Or Hives report and make more profitable business decisions.This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Briquilimab in Chronic Urticaria Or Hives Drug Details: Briquilimab (AMG-191)...
-
Product Insights
Thalassemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Thalassemia - Drugs In Development, 2023’, provides an overview of the Thalassemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Thalassemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key...
-
Product Insights
Chronic Urticaria Or Hives – Drugs In Development, 2023
Global Markets Direct’s, ‘Chronic Urticaria Or Hives - Drugs In Development, 2023’, provides an overview of the Chronic Urticaria Or Hives pipeline landscape. The report provides comprehensive information on the therapeutics under development for Chronic Urticaria Or Hives, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press...
-
Product Insights
Beta Thalassaemia – Drugs In Development, 2023
Global Markets Direct’s, ‘Beta Thalassaemia - Drugs In Development, 2023’, provides an overview of the Beta Thalassaemia pipeline landscape. The report provides comprehensive information on the therapeutics under development for Beta Thalassaemia, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an...